Rare disease pharmaceutical company enhances customer interactions
across channels and markets for successful launch of its first product
PLEASANTON, Calif.--(BUSINESS WIRE)--
Veeva
Systems (NYSE:VEEV) announced today that Santhera Pharmaceuticals
selected Veeva
CRM and Veeva
OpenData as a commercial software and data platform for its first
product launch. The rare disease pharmaceutical company is adopting Veeva
Commercial Cloud solutions to establish a consistent, global
approach to commercialization.
Accurate customer data is foundational for commercial excellence,
especially with today’s growing number of stakeholders. Veeva brings
together complete customer data and multichannel engagement to help life
sciences organizations enhance their interactions with healthcare
professionals worldwide. Field teams have up-to-date customer reference
data where they need it most to enable faster and tailored interactions.
When users submit data change requests, they are properly verified and
updated in hours versus the industry average of 10 or more days.
A recent survey showed that the majority of companies struggle with
customer data quality issues. Incorrect physician addresses, not knowing
which doctors to contact, or outdated information about specialty and
license status create frustration among field teams and impact
efficiency. Bad data can also lead to compliance risks. That’s why
according to our research 78% of companies have initiatives underway to
improve data quality within the next two years.1
“There is a major transition happening across the industry as companies
focus on better customer data for improved commercial effectiveness,”
said Guillaume Roussel, director of strategy for Veeva OpenData. “Veeva
OpenData and Veeva CRM are changing how the life sciences industry
sources and manages data to drive greater speed, productivity, and
execution globally.”
Veeva recently announced that 100 customers have adopted Veeva OpenData,
including Allergan, who like other life sciences companies, has moved to
Veeva OpenData for more up-to-date and complete customer reference data.
Read the recent
news to learn how Veeva OpenData is helping the industry overcome
longstanding data quality challenges.
About Veeva OpenData
Veeva OpenData provides comprehensive and accurate HCP, HCO,
affiliations, email, and compliance data, right where customers need it.
Veeva OpenData can help customers achieve greater commercial success and
enable everything from multichannel customer engagement to compliant
interaction. Today, Veeva OpenData provides access to approximately 20
million HCPs and their HCO affiliations, covering all specialties and
classes of trade, spanning 39 countries.
Additional Information
For more on Veeva OpenData: veeva.com/OpenData
For more on Veeva CRM: veeva.com/CRM
Connect with Veeva on LinkedIn: linkedin.com/company/veeva-systems
Follow @veevasystems on Twitter: twitter.com/veevasystems
Like Veeva on Facebook: facebook.com/veevasystems
About Veeva Systems
Veeva Systems Inc. is a leader in cloud-based software for the global
life sciences industry. Committed to innovation, product excellence, and
customer success, Veeva has more than 525 customers, ranging from the
world's largest pharmaceutical companies to emerging biotechs. Veeva is
headquartered in the San Francisco Bay Area, with offices in Europe,
Asia, and Latin America. For more information, visit veeva.com.
Forward-looking Statements
This release contains forward-looking statements, including the market
demand for and acceptance of Veeva’s products and services, the results
from use of Veeva’s products and services, and general business
conditions, particularly in the life sciences industry. Any
forward-looking statements contained in this press release are based
upon Veeva’s historical performance and its current plans, estimates,
and expectations, and are not a representation that such plans,
estimates, or expectations will be achieved. These forward-looking
statements represent Veeva’s expectations as of the date of this press
announcement. Subsequent events may cause these expectations to change,
and Veeva disclaims any obligation to update the forward-looking
statements in the future. These forward-looking statements are subject
to known and unknown risks and uncertainties that may cause actual
results to differ materially. Additional risks and uncertainties that
could affect Veeva’s financial results are included under the captions,
“Risk Factors” and “Management’s Discussion and Analysis of Financial
Condition and Results of Operations,” in the company’s filing on Form
10-Q for the period ended April 30, 2017. This is available on the
company’s website at veeva.com
under the Investors section and on the SEC’s website at sec.gov.
Further information on potential risks that could affect actual results
will be included in other filings Veeva makes with the SEC from time to
time.
1 http://go.veeva.com/2016-european-life-sciences-survey-on-customer-data
View source version on businesswire.com: http://www.businesswire.com/news/home/20170628005334/en/
Source: Veeva Systems Inc.